investorscraft@gmail.com

Investing in Arcutis Biotherapeutics, Inc. (ARQT)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)55.66414
Intrinsic value (DCF)55.66414
Graham-Dodd Method0.00-100
Graham Formula0.00-100

Company description

ARQT is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for debilitating skin diseases and conditions. Founded in 2001 and headquartered in San Francisco, California, the company primarily focuses on treatments for rare and underserved skin diseases, including epidermolysis bullosa, a genetic disorder characterized by extremely fragile skin. ARQT utilizes a unique approach that combines its expertise in RNA interference (RNAi) with cutting-edge technology to develop therapeutics that can target specific genes associated with these skin diseases. The company's flagship product, ARQ-151, is currently in Phase 3 clinical trials for the treatment of atopic dermatitis, a common and chronic skin condition. In addition to its clinical pipeline, ARQT also has a strong research and development program that focuses on identifying and validating new targets for potential treatments. With a team of experienced leaders and highly specialized scientists, ARQT is dedicated to improving the lives of patients with skin diseases and bringing hope and relief to those who often have limited treatment options.
HomeMenuAccount